Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma

American Journal of Hematology

Volumn 91, Issue 9, 2016, Pages 923-930

  Jardin, Fabrice ^a   Pujals, Anais ^b   Pelletier, Laura ^b   Bohers, Elodie ^a   Camus, Vincent ^a   Mareschal, Sylvain ^a   Dubois, Sydney ^a   Sola, Brigitte ^c   Ochmann, Marlène ^d   Lemonnier, François ^b   Viailly, Pierre Julien ^a   Bertrand, Philippe ^a   Maingonnat, Catherine ^a   Traverse Glehen, Alexandra ^d   Gaulard, Philippe ^b   Damotte, Diane ^e   Delarue, Richard ^f   Haioun, Corinne ^b   Argueta, Christian ^g   Landesman, Yosef ^g   Salles, Gilles ^h   Jais, Jean Philippe ^g   Figeac, Martin ⁱ   Copie Bergman, Christiane ^b   Molina, Thierry Jo ^g   Picquenot, Jean Michel ^a   Cornic, Marie ^a   Fest, Thierry ^d   Milpied, Noel ^j   Lemasle, Emilie ^a   Stamatoullas, Aspasia ^a   Moeller, Peter ^k   Dyer, Martin J S ^l   Sundstrom, Christer ^m   Bastard, Christian ^a   Tilly, Hervé ^a   Leroy, Karen ^b   more..

^a CENTRE HENRI BECQUEREL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Karyopharm Therapeutics Inc   (United States)

ⁱ Functional Genomic Platform   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF ULM   (Germany)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

^m Leicester ^*  (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXPORTIN 1; MESSENGER RNA; PREDNISOLONE; PREDNISONE; RITUXIMAB; SELINEXOR; VINCRISTINE; VINDESINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CODON; DRUG PROTEIN BINDING; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PRIORITY JOURNAL; WILD TYPE;

EID: 84983077439     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24451     Document Type: Article

References (54)

1. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–862.
2. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871–3879.
3. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: Do they require a unique therapeutic approach? Blood 2015;125:33–39.
4. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118:2659–2669.
5. Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014;46:329–335.
6. Gebauer N, Hardel TT, Gebauer J, et al. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma. Anticancer Res 2014;34:5503–5507.
7. Mareschal S, Dubois S, Viailly P, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer, in press.
8. Dubois S, Viailly PJ, Mareschal S, et al. Next generation sequencing in diffuse large B cell lymphoma highlights molecular divergence and therapeutic opportunities: A LYSA study. Clin Cancer Res 2016;22:2919–2928.
9. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28:108–117.
10. Lin DC, Hao JJ, Nagata Y, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014;46:467–473.
11. Bond J, Bergon A, Durand A, et al. Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood 2014;124:3023–3025.
12. Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013;161:117–127.
13. Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012;120:4621–4634.
14. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
15. Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet 2011;378:1858–1867.
16. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol 2013;14:525–533.
17. Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica 2011;96:1136–1143.
18. Ketterer N, Coiffier B, Thieblemont C, et al. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol Off J Eur Soc Med Oncol ESMO 2013;24:1032–1037.
19. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: The missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005;29:1411–1421.
20. Moller P, Bruderlein S, Strater J, et al. MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int J Cancer J Int Cancer 2001;92:348–353.
21. Nacheva E, Dyer MJ, Metivier C, et al. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood 1994;84:3422–3428.
22. Sambade C, Berglund M, Lagercrantz S, et al. U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. Int J Cancer J Int Cancer 2006;118:555–563.
23. Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymph 2016;1–9. [Epub ahead of print] PMID: 26883583.
24. Mareschal S, Dubois S, Lecroq T, et al. Rgb: A scriptable genome browser for R. Bioinformatics 2014;30:2204–2205.
25. Li Q, Birkbak NJ, Gyorffy B, et al. Jetset: Selecting the optimal microarray probe set to represent a gene. BMC Bioinform 2011;12:474.
26. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
27. Kau TR, Schroeder F, Ramaswamy S, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003;4:463–476.
28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol Off J Am Soc Clin Oncol 1999;17:1244.
29. Dong X, Biswas A, Suel KE, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009;458:1136–1141.
30. Saunders CT, Baker D. Evaluation of structural and evolutionary contributions to deleterious mutation prediction. J Mol Biol 2002;322:891–901.
31. Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46:310–315.
32. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996;87:1571–1578.
33. Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007;46:406–415.
34. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520–13525.
35. Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015;125:1061–1072.
36. Aguiar RC, Takeyama K, He C, et al. B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J Biol Chem 2005;280:33756–33765.
37. Han X, Wang J, Shen Y, et al. CRM1 as a new therapeutic target for non-Hodgkin lymphoma. Leuk Res 2015;39:38–46.
38. Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications. Leukemia 2014;28:155–165.
39. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006;25:2679–2684.
40. Ritz O, Guiter C, Castellano F, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009;114:1236–1242.
41. Dunleavy K, Grant C, Eberle FC, et al. Gray zone lymphoma: Better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malignancy Rep 2012;7:241–247.
42. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392–1399.
43. Yuan J, Wright G, Rosenwald A, et al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling. Am J Surg Pathol 2015;39:1322–1330.
44. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005;105:2535–2542.
45. Marg A, Shan Y, Meyer T, et al. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 2004;165:823–833.
46. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471:377–381.
47. Xie L, Ritz O, Leithauser F, et al. FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma. Oncotarget 2014;5:5392–5402.
48. Mao L, Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharma Des 2013;19:2318–2325.
49. Raval A, Weissman JD, Howcroft TK, et al. The GTP-binding domain of class II transactivator regulates its nuclear export. J Immunol 2003;170:922–930.
50. Muqbil I, Kauffman M, Shacham S, et al. Understanding XPO1 target networks using systems biology and mathematical modeling. Curr Pharma Des 2014;20:56–65.
51. Swameye I, Muller TG, Timmer J, et al. Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc Natl Acad Sci USA 2003;100:1028–1033.
52. Neggers JE, Vercruysse T, Jacquemyn M, et al. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol 2015;22:107–116.
53. Gravina G, Senapedis W, McCauley D, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 2014;7:85.
54. Yoshimura M, Ishizawa J, Ruvolo V, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 2014;105:795–801.